2024-10-20 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**Company Overview:** Pfizer Inc. is a multinational pharmaceutical corporation that develops and manufactures medicines and vaccines.

**1. Performance Comparison:**

* **Cumulative Return:** PFE -11.65%, VOO (S&P 500) 137.88% 
* **Performance Gap:** -149.53% (relative gap: 0.09). This signifies that PFE has underperformed VOO significantly, currently sitting at the 9th percentile of its historical performance relative to VOO.

**2. Recent Price Movement:**

* **Closing Price:** $29.22
* **5-day Moving Average:** $29.34
* **20-day Moving Average:** $29.13
* **60-day Moving Average:** $29.23
* **Price Trend:** The stock is currently trading slightly below its recent moving averages, indicating a slight bearish trend.

**3. Technical Indicators:**

* **RSI:** 53.02 (neutral)
* **PPO:** 0.08 (positive)
* **Delta_Previous_Relative_Divergence:** -0.09 (short-term bearish)
* **Expected_Return:** 0.0% (projected long-term return relative to S&P 500)

**4. Recent Earnings and Outlook:**

| Date      | EPS     | Expected EPS |
|-----------|---------|--------------|
| 2024-07-30 | 0.6     | 0.458        |
| 2024-05-01 | 0.82    | 0.516        |
| 2024-01-30 | 0.1     | -0.19         |
| 2023-10-31 | -0.17   | -0.32         |
| 2023-08-01 | 0.67    | 0.56         |

Pfizer has consistently surpassed analysts' EPS estimates in recent quarters, showcasing strong earnings performance. This trend suggests positive momentum for the company. The latest earnings release for Q2 2024 revealed an EPS of $0.60, exceeding the expected $0.458.

**5. News and Recent Issues:**

* **Market Outlook:** The market outlook for PFE remains cautiously optimistic due to its strong earnings performance, diversification efforts, and continued growth potential. However, there are some concerns regarding competition and patent expirations.
* **Analyst Opinions:** The majority of analysts have a "Hold" or "Buy" rating on PFE, with a consensus target price of $35.00.
* **Performance Highlights:** Pfizer's recent performance has been driven by its Comirnaty COVID-19 vaccine and its strong pipeline of new drugs. The company is also focusing on expanding its presence in emerging markets.

**6. Overall Analysis:**

Despite its recent underperformance against VOO, PFE demonstrates a solid financial foundation with consistently positive earnings and a robust pipeline of new drugs. The stock is currently trading below its moving averages, suggesting a slight bearish trend in the short term. However, the positive earnings reports and analyst outlook indicate potential for future growth.  

**7. Recommendation:**

While PFE has underperformed VOO in the past, its strong fundamentals and promising future prospects suggest potential for recovery and growth. This makes it a potentially attractive investment for long-term investors with a moderate risk tolerance. 

**Note:** This analysis is based on publicly available information and should not be considered financial advice. 
